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Hypertension guidelines stress that patients with severe
hypertension (systolic blood pressure (BP)X180
or diastolic BPX110mmHg) require multiple drugs to
achieve control and should have close follow-up
to prevent adverse outcomes. However, little is known
about the epidemiology or actual management of these
patients. We retrospectively studied 59 207 veterans
with hypertension. Patients were categorized based on
their highest average BP over an 18-month period
(1 July 1999 to 31 December 2000) as controlled
(o140/90mmHg), mild (140–159/90–99mmHg), moderate
(160–179/100–109mmHg) and severe hypertension. We
examined severe hypertension prevalence, pattern, dura-
tion, associated patient characteristics, time to subse-
quent visit, percentage of visits with a medication
increase, and final BP control and antihypertensive
medication adequacy. Twenty-three per cent hadX1 visit
with severe hypertension, 42% of whom had at least two
such visits; median day with severe hypertension was 80
(range 1–548). These subjects were significantly older,
more likely black, and with more comorbidities than other
hypertension subjects. Medication increases occurred at
20% of visits with mild hypertension compared to 40%
with severe hypertension; Po0.05). At study end, 76% of
patients with severe hypertension remained uncontrolled;
severe hypertension subjects with uncontrolled BP were
less likely to be on adequate therapy than those with
controlled BP (43.7 vs 45.4%). Among hypertensive
veterans, severe hypertension episodes are common.
Many subjects had relatively prolonged elevations, with
older, sicker subjects at highest risk. Although, follow-up
times are shorter and antihypertensive medication use
greater in severe hypertension subjects, they are still
not being managed aggressively enough. Interventions
to improve providers’ management of these high-risk
patients are needed.
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Introduction
Hypertension is among the most prevalent chronic
conditions worldwide; with rates as high as 70%
among adults in developed countries such as
Poland.1 Although hypertension is usually asympto-
matic, it may be associated with considerable
morbidity and mortality. The higher the blood
pressure (BP), the greater the risk for adverse
outcomes including development of coronary artery
disease, congestive heart failure, stroke and kidney
disease.2 Hypertension treatment has been clearly
shown to reduce this risk.2–4
Accordingly, the current World Health Organi-
zation/International Society of Hypertension and
the European Society of Hypertension guidelines
and the prior Joint National Committee on Preven-
tion, Detection, Evaluation and Treatment of High
Blood Pressure (JNC) guidelines classify BP into
grades or stages based on the absolute BP level.5–7
Although absolute cardiovascular risk is based not
only on BP levels, but associated cardiovascular
risk factors or target organ damage, individuals with
the highest levels, grade/stage3 or severe hyper-
tension (that is, systolic BPX180mmHg or diastolic
BPX110mmHg)5,8 have a 20–30% 10-year risk of
cardiovascular disease, that increases to very high
risk, 430%, in the presence of any risk factors or
target organ damage.5 Further, these subjects are also
at high short-term risk for serious cardiovascular
events, the risk increasing with the degree and
speed of elevation. Because of this, guidelines also
stress that such patients should have close follow-
up with reassessment at most within 1 week, and
will require multiple drugs to achieve control.5,9,10
Although much has been written about the
epidemiology and management of the general
hypertension population, relatively little is known
about these issues in those with severe hyper-
tension. Limited cross-sectional data suggest a
prevalence among those with hypertension in the
JHHOpen
Received 8 October 2008; revised 10 April 2009; accepted 11
April 2009; published online 14 May 2009
Correspondence: Dr AM Borzecki, Center for Health Quality
Outcomes and Economic Research, Bedford VA Hospital (152),
200 Springs Road, Bedford, MA, 1730, USA.
E-mail: amb@bu.edu
Journal of Human Hypertension (2010) 24, 9–18
& 2010 Macmillan Publishers Limited All rights reserved 0950-9240/10 $32.00
www.nature.com/jhh
8–19% range.10–13 How long such patients are
exposed to high BPs, or how they are being managed
in actual practice is relatively unknown, with
existing data based on small samples and select
populations.12–14
The purpose of the present study was to examine
the following issues with respect to patients with
severe hypertension: (1) what is the epidemiology of
severe hypertension, in terms of prevalence, pattern
of severe hypertension and duration of severe
hypertension? (2) what patient characteristics are
associated with severe hypertension? (3) how are
patients with severe hypertension being managed in
everyday practice, including time to next visit,
percentage of visits with a medication increase and
number of BP medications by final BP control?
Materials and methods
Study population
The study population is previously described.15
Briefly, we identified individuals with hypertension
who were receiving regular outpatient care at
geographically diverse sites within the largest inte-
grated health-care system in the United States, the
Veterans Health Administration (VA), using the VA’s
National Patient Care Database (NCPD) through
2000, eligible subjects: (1) had at least two NPCD-
listed hypertension diagnoses, ICD-9-CM code 401,
between 1 July 1997 and 30 June 1999; and (2) were
regular VA users (that is, X3 NPCD-listed visits to a
general medicine or subspecialty medical clinic
between 1 July 1999 and 31 December 2000).
Subjects were followed from 1 July 1999 through
31 December 2000. The study protocol was
approved by the Bedford VA Hospital’s institutional
review board.
Data collection
Data sources were the Veterans Health Information
Systems and Technology Architecture (VISTA), that
is, the VA’s electronic record system, the NPCD and
Medicare files. VISTA, maintained at each site,
contains multiple files including clinical data such
as vital signs, laboratory results, pharmacy records
and provider notes. (We previously found the vitals
file very complete with provider notes contributing
minimal additional BP information.)16 VISTA also
contains diagnoses and procedure information from
all outpatient visits and inpatient stays, which is
transferred to a central data repository and incorpo-
rated into the NPCD.17
Demographics and comorbidities were obtained
from the NPCD (1998 to 2000 inclusive), supple-
mented by Medicare denominator, inpatient and
outpatient files (MEDPAR, Carrier and Outpatient
files). We used the Medicare denominator file as our
primary race source because this is patient identi-
fied and supplemented this with VA race data.
Baseline comorbidities were identified by the pre-
sence of specified ICD-9-CM codes in the 12 months
preceding and including the index visit.15 Height,
weight and BP were obtained from VISTAvitals, and
medications from VISTA pharmacy files (1 July 1999
to 31 December 2000).
Analyses
Available BPs were averaged at each visit. All visits
during 1 July 1999 through 31 December 2000
were categorized according to the average systolic
and diastolic BPs as follows: controlled (o140/
90mmHg), mild (140–159/90–99mmHg), moderate
(160–179/100–109mmHg) and severe (X180/
110mmHg) hypertension. Patients were then
grouped based on their visit with the highest average
BP category unless otherwise specified. If systolic
and diastolic BPs fell into different categories, the
higher category was used. Among patients with
more than one severe hypertension episode, patient
level analyses considered only the first episode
unless otherwise indicated.
Objective 1: examine the epidemiology of patients
with severe hypertension. We first determined the
prevalence of severe hypertension in our cohort
based on the number of subjects who had at least
one visit with severe hypertension divided by the
total sample of hypertension patients. We also
looked at the proportion of all visits with severe
hypertension and the median number of visits with
severe hypertension per patient. Next, we character-
ized the pattern of severe hypertension by determin-
ing the following proportions: (1) those who had a
single visit with severe hypertension, with no severe
hypertension at the next visit (that is, an isolated
spike in their BP); (2) those who had severe
hypertension at two or more consecutive visits
(persistent severe hypertension); (3) those who had
an intervening visit with a lower BP but then
another visit with severe hypertension (recurrent
severe hypertension). We further determined the
median number of recurrences per patient. In
addition, we examined time in days to a subsequent
visit with a BP o180/110mmHg as a proxy for the
duration of (that is, exposure to) severe hyperten-
sion, and compared among severe hypertension
groups. We summed these time periods for patients
with recurrent episodes. (This was examined first by
censoring subjects with no visit after the severe
hypertension visit at either the last day of the study
period or death, and then by excluding them.)
Objective 2: patient characteristics associated with
severe hypertension. We next compared patients
with severe hypertension to subjects without severe
hypertension, grouped by highest BP category, with
respect to age, gender, race, baseline comorbidities
(including cardiovascular risk factors and pre-
existing cardiovascular conditions, and Charlson
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index),18,19 body mass index (BMI). We also com-
pared severe hypertension subgroups with respect
to these same characteristics.
We used w2-analysis for categorical variables, and
t-tests, one-way analysis of variance (ANOVA) with
Tukey’s multiple comparison procedure, or Wilcox-
on rank-sum tests as appropriate for continuous
variables.
As part of a sensitivity analysis, we repeated
objectives 1 and 2 assigning subjects to BP categories
based on the first visit of the study period.
Objective 3: examine the management of patients
with severe hypertension. We next examined
actions potentially under clinician control. The
following analyses were carried out at the visit
level: (1) we determined the time in days to the next
visit that included a BP assessment following a visit
with severe hypertension. We used Wilcoxon rank-
sum tests to compare the median interval to the next
visit among severe hypertension subgroups, and
between visits with severe hypertension to visits
with moderate hypertension, mild hypertension or
controlled BP. (2) We then examined the percentage
of visits associated with a medication increase.
To determine medication increases at a visit, we
defined baseline medication use based on the
6-month period preceding study entry (that is, we
examined medication data out to 1 January 1999);
using methods we previously developed, a patient
was considered to have an increase at a given visit if
the dose of an existing medication was increased or
a new medication was started.20,21 We compared the
proportion of visits with a medication increase
among the severe hypertension subgroups then
compared among visits with moderate, mild hyper-
tension or controlled BP using w2-tests. We also
looked at the impact of this increase on BP control at
the subsequent visit for the severe hypertension
group.
Although we lacked information on specialty
referrals for BP management or to exclude secondary
hypertension, as a proxy, we examined differences
in proportions of patients seen in subspecialty
clinics at which BP management might be addressed
by w2-analysis and generating 95% confidence
intervals. These clinics included hypertension,
renal, cardiology and endocrinology clinics. We
further looked at the frequency of these visits with
a primary diagnoses related to hypertension (ICD-9-
CM codes 401, 402, 403, 404 and 405 (secondary
hypertension)) and the frequency of any 405 code at
these visits.
To examine medication use and BP control at
study end, we then categorized subjects based on
their highest average BP at a visit before the last
study visit. We compared the percentage of patients
who achieved a BPo140/90mmHg at the last study
visit by BP group. We next compared BP groups by
mean number of prescribed antihypertensive med-
ications (using ANOVA), percentage of subjects on
each major class of antihypertensive medication and
the percentage on adequate therapy defined as a
regimen containing at least three different classes
of drugs at least one of which had to be a loop
or thiazide diuretic9 at the last study visit using
w2-tests. We then examined the mean number of
prescribed antihypertensive medications at the time
of the last visit by prior highest BP category and
final BP control (that is, BPo140/90mmHg; yes/no)
using linear regression models, comparing both
within BP groups, and across groups for controlled
vs uncontrolled. We also repeated analyses compar-
ing among severe hypertension subgroups. Finally,
we examined adequacy of antihypertensive therapy
at the last study visit and final BP control. Within
each BP group defined by the highest BP before the
last study visit, we used w2-tests to examine like-
lihood of adequate therapy at study end by final BP
control (yes/no); we also compared adequacy across
BP categories. We performed similar comparisons
among severe hypertension groups.
Results
Objective 1
Our total sample consisted of 59 207 subjects. The
mean age was 65 years: 58% were white and 97%
were men.15 Twenty-three per cent (N¼ 13 735) had
at least one visit with severe hypertension; among
these subjects the median number of such visits was
1 (range 1–57). Six per cent of all visits (21 992/
325 105) were associated with severe hypertension.
Of note, 87% of visits with a BP ofX180/110mmHg
had only one BP documented on the day of the visit.
Of the severe hypertension group, 18% had severe
hypertension at two or more consecutive visits
(persistent), 23% had one or more intervening visits
with a lower BP but then another visit with severe
hypertension (recurrent); 58% had a single visit
with a BPX180/110mmHg (isolated spike). In 17%
of subjects with an isolated spike, there was no
subsequent documented visit. The median number
of recurrences among the severe hypertension group
was 0, range 0–34 (interquartile range 0–1). The
median number of days with severe hypertension
overall was 80 (range 1–548; Table 1) and varied
Table 1 Total exposure to severe hypertension
BP category Exposure to severe hypertension
Days, median (range) a
Severe hypertension, overall 80 (1–548)
Persistent 182 (2–548)
Recurrent 103 (2–534)
Isolated spike 50 (1–549)
Abbreviation: BP, blood pressure.
aSignificant difference with respect to number of days exposed
between groups (Po0.001).
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significantly by severe hypertension subgroup.
(Overall exposure did not change significantly if
we excluded subjects with a single visit.)
Categorizing subjects using the first study period
visit, 7% of subjects had severe hypertension, of
whom 27% had persistent, 28% had recurrent and
45% had an isolated spike. Exposure trends were
similar.
Objective 2
Compared to subjects with lower BPs, severe
hypertension subjects were older, (67.0þ 10.8 vs
64.6þ 11.2 years; Po0.05), were more likely to be
black (24 vs 16%; Po0.05) and women (3.3 vs 2.7%,
Po0.05) compared to all other subjects combined
(N¼ 45 472). They also had more total comorbidities
(for example, Charlson index 1.4þ 1.3 vs 1.2þ 1.2,
Po0.05) and a higher prevalence of specific comor-
bidities such as diabetes, renal disease and periph-
eral vascular disease; although when further divided
into BP categories, the controlled BP group had the
highest prevalence of coronary artery disease, con-
gestive heart failure and hyperlipidaemia. (See
Table 2 for comparisons among BP categories.)
Among severe hypertension subgroups, the recur-
rent and persistent were similar with respect to age
and race distribution, but the recurrent had the most
comorbidities followed by the persistent then the
isolated spike group. The isolated spike group was
younger and more likely to be white (see Table 3).
Similar trends were seen when subjects were
categorized by the first study visit (data not shown;
available from authors).
Objective 3
The median time to a subsequent visit after
presentation was 42 days (range 1–503) for severe
hypertension, 52 days (1–513) for controlled BP, 60
days (1–518) for mild and 55 (1–496) for moderate
hypertension visits (Po0.05 for between-group
differences).
Hypertension medication increases occurred at
40% of severe hypertension, 10% of controlled, 20%
of mild and 32% of moderate hypertension visits
(Po0.05). Among visits with severe hypertension,
medications were increased at 41% of visits with
severe hypertension among the persistent group,
36% of the recurrent group and 42% of the isolated
spike group (Po0.05). If a medication was increased
at a given visit with severe hypertension, BP was
controlled 13.2% of the time at the next visit, versus
12.5% of next visits if there was no medication
increase. (This difference was not significant (NS)).
The proportion of patients seen in a subspecialty
clinic at which BP management might be addressed
not surprisingly tended to increase with increasing
BP category, and was significantly higher in the
severe hypertension group (except for cardiology
clinic visits) presumably in part driven by the higher
prevalence of renal disease or diabetes in the more
severe group (Table 4). The frequency of such visits
associated with a primary diagnosis of hypertension
ranged from 6.2% among the controlled group, 8.9%
of the mild, 13.3% of the moderate, to 20.0% among
the severe hypertension group. In severe hyperten-
sion subgroup, this ranged from 17.5% among the
isolated spike group, 18.0% among the recurrent
group and 29.8% among the persistent group (Po0.5
Table 2 Baseline patient characteristics by highest BP group
Characteristic Controlled
N¼5170
Mild
N¼19290
Moderate
N¼21012
Severe
N¼ 13735
Age, mean (s.d.), years 63.7 (11.3) 63.8 (11.2) 65.5 (10.9) 67.0 (10.8)a
Gender, female, no. (%) 121 (2.3) 516 (2.7) 604 (2.9) 453 (3.3)a
Race, no. (%), white 3988 (77.1) 14 563 (75.5) 15 573 (74.1) 9545 (69.5)a
Black 659 (12.8) 2,842 (14.7) 3,741 (17.8) 3302 (24.0)a
Hispanic 71 (1.4) 233 (1.2) 300 (1.4) 153 (1.1)
Others 108 (2.1) 358 (1.9) 341 (1.6) 221 (1.6)
Unknown 344 (6.7) 1294 (6.7) 1057 (5.0) 514 (3.7)a
BMI, mean (s.d.), kgm2 28.8 (5.4) 29.4 (5.5) 29.5 (5.8) 29.2 (6.1)a
Comorbidities
Cerebrovascular disease, no. (%) 669 (12.9) 2261 (11.7) 2781 (13.2) 2305 (16.8)a
Congestive heart failure, no. (%) 1055 (20.4) 2338 (12.1) 2354 (11.2) 1814 (13.2)a
Coronary artery disease, no. (%) 2392 (46.3) 6998 (36.3) 7128 (33.9) 4802 (35.0)a
Diabetes, no. (%) 1584 (30.6) 5841 (30.3) 6996 (33.3) 5263 (38.3)a
Hyperlipidaemia, no. (%) 2563 (49.6) 8927 (46.3) 8895 (42.3) 5151 (37.5)a
Peripheral vascular disease, no. (%) 532 (10.3) 1688 (8.8) 2141 (10.2) 1760 (12.8)a
Renal disease, no. (%) 340 (6.6) 1050 (5.4) 1378 (6.6) 1430 (10.4)a
Tobacco use, no. (%) 503 (9.7) 1897 (9.8) 1951 (9.3) 1219 (8.9)a
Charlson index, mean (s.d.) 1.3 (1.4) 1.2 (1.2) 1.2 (1.2) 1.4 (1.3)a
Abbreviations: BMI, body mass index; s.d., standard deviation.
aPo0.05 for among-group comparisons and pair-wise comparisons; the severe hypertension group was significantly different than the three other
hypertension groups with respect to all the characteristics listed. However, with respect to race, the prevalence of Hispanics in the severe
hypertension group was only significantly different compared to the moderate hypertension group.
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for between-group differences). The frequency of a
code for secondary hypertension ranged from 0%
among endocrinology visits, 0.1% for cardiology,
0.9% for renal, to 2.8% of all hypertension clinic
visits.
When categorized by the highest available BP
before the last visit of the study, at the end of study
24% of the severe hypertension group had con-
trolled BP, compared to 73% of the controlled, 51%
of mild and 33% of the moderate group (Po0.05).
For the severe hypertension subgroups, the isolated
spike group was most likely to be controlled (27%),
followed by the recurrent (21%) and the persistent
groups (16%; Po0.05 for between-group differ-
ences). (Of note, 1390 subjects with only one visit
with a BP were excluded from this analysis; 500 had
controlled, 525 had mild, 243 had moderate and 122
(9%) had severe hypertension. We found similar
results to those reported below if we included these
subjects in analyses and assumed they had an
additional visit and their BP category was stable
(data not shown; available from authors).)
At the end of study, the mean number of BP
medications increased significantly with increasing
BP category (Table 5; Figure 1). In addition, severe
hypertension patients were significantly more likely
to be on all classes of antihypertensives compared to
the other groups (Table 5). Among severe hyperten-
sion subgroups, the persistent and recurrent sub-
groups were on more medications at study end than
Table 3 Baseline patient characteristics by severe hypertension group
Characteristic Persistent severe
N¼ 2517
Recurrent severe
N¼ 3210
Isolated spike
N¼ 8008
Age, mean (s.d.), years 67.4 (10.8) 67.7 (10.6) 66.6 (10.9)a
Gender, female, no. (%) 80 (3.2) 104 (3.2) 269 (3.4) NS
Race, no. (%), white 1631 (64.8) 2144 (66.8) 5770 (72.1)a
Black 734 (29.2) 910 (28.4) 1658 (20.7)a
Hispanic 26 (1.0) 42 (1.3) 85 (1.1)
Others 40 (1.6) 40 (1.3) 141 (1.8)
Unknown 86 (3.4) 74 (2.3) 354 (4.4)a
BMI, mean (s.d.), kgm2 29.2 (6.1) 29.0 (6.1) 29.4 (6.1)a
Comorbidities
Cerebrovascular disease, no. (%) 470 (18.7) 612 (19.1) 1223 (15.3)a
Congestive heart failure, no. (%) 350 (13.9) 490 (15.3) 974 (12.2)a
Coronary artery disease, no. (%) 834 (33.1) 1217 (37.9) 2751 (34.4)a
Diabetes, no. (%) 1064 (42.3) 1396 (43.5) 2803 (35.0)a
Hyperlipidaemia, no. (%) 912 (36.2) 1178 (36.7) 3061 (38.2)a
Peripheral vascular disease, no. (%) 323 (12.8) 514 (16.0) 923 (11.5)a
Renal disease, no. (%) 291 (11.6) 465 (14.5) 674 (8.4%)a
Tobacco use, no. (%) 211 (8.4%) 287 (8.9%) 721 (9.0) NS
Charlson index, mean (s.d.) 1.4 (1.3) 1.6 (1.4) 1.3 (1.3)a
Abbreviations: BMI, body mass index; NS, not significant; s.d., standard deviation.
aPo0.05 for among-group comparisons and pair-wise comparisons; recurrent and persistent groups were similar with respect to age, white and
black race distribution, BMI, prevalence of cerebrovascular disease, congestive heart failure, diabetes and hyperlipidaemia.
Table 4 Percentage of patients with subspecialty clinic visitsa
Highest BP category Hypertension
clinic % (95% CI)
Renal clinic %
(95% CI)
Cardiology
clinic % (95% CI)
Endocrinology
clinic % (95% CI)
Any subspecialty
clinicb % (95% CI)
Controlled (N¼ 5170) 0.2 (0.1–0.4) 0.6 (0.4–0.8) 9.0 (8.2–9.8) 1.5 (1.2–1.7) 10.6 (9.8–11.5)
Mild (N¼19 290) 0.3 (0.2–0.4) 0.9 (0.8–1.1) 8.6 (8.2–9.0) 1.6 (1.4–1.8) 10.8 (10.3–11.2)
Moderate (N¼21 012) 0.4 (0.3–0.5) 1.7 (1.5–1.8) 8.6 (8.2–8.9) 1.9 (1.7–2.1) 11.5 (11.1–12.0)
Severe (N¼ 13735) 0.8 (0.7–1.0) 3.7 (3.4–4.0) 8.9 (8.4–9.4) 2.2 (2.0–2.5) 14.1 (13.6–14.7)
Persistent (N¼2517) 1.2 (0.9–1.7) 4.6 (3.8–5.5) 7.2 (6.3–8.3) 2.5 (1.9–3.1) 13.7 (12.4–15.1)
Recurrent (N¼ 3210) 1.0 (0.7–1.4) 6.2 (5.4–7.1) 11.7 (10.6–12.8) 2.8 (2.3–3.4) 19.4 (18.0–15.1)
Isolate spike (N¼8008) 0.7 (0.5–0.9) 2.4 (2.1–2.7) 8.3 (7.8–9.0) 2.0 (1.7–2.3) 12.2 (11.5–12.9)
Abbreviations: BP, blood pressure; CI, confidence interval.
Non-overlapping of CIs indicates the proportions (percentages) are significantly different from each other.
aClinics at which hypertension is likely to be treated.
bAny subspecialty clinic: hypertension, renal, cardiology or endocrinology.
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the isolated spike subgroup (Table 5; Po0.05 for
between-group differences). The proportion on each
medication class was significantly lower for the
isolated spike group than the persistent or recurrent
group, except for ACEI/ARB use which was similar
to the recurrent group (Table 5). Despite a trend
towards higher use of each medication class among
the persistent group compared to the recurrent, the
differences were not significant.
Across all BP groups, those with controlled BP at
study end (o140/90mmHg) were on more medica-
tions than those with uncontrolled BP (although this
difference was not significant for the severe hyper-
tension group; Figure 1). Within severe hyperten-
sion subgroups, the mean number of medications at
study end was only significantly different between
controlled and uncontrolled subjects for the isolated
spike group (Figure 1).
Use of three or more medications including a
diuretic at the last visit increased by increasing
preceding highest BP category (although the differ-
ence between the controlled and mild groups was
not significant) (see Table 5 and Figure 2). Among
the severe hypertension subgroups, those with
persistent or recurrent elevations were more likely
to be on adequate multi-drug therapy compared to
the isolated spike group (Table 5). Similar to the
medication class analysis, the proportions on ade-
quate therapy in the persistent and recurrent groups
were not significantly different (Table 5).
When examining adequacy of therapy and final
BP control, subjects with uncontrolled BP at the last
visit were less likely to be on adequate multi-drug
therapy than those with controlled BP within any
given BP group or severe hypertension subgroup
(Figure 2), although differences were not significant
for the severe hypertension group (45.4 vs 43.7%,
NS; Figure 2). In subgroups, differences were only
significant among the isolated spike subgroup
(Figure 2).
Discussion
This is the largest study to date examining the
epidemiology and management of patients with
severe hypertension. This is also the first to
characterize the pattern of severe hypertension, to
examine management of such patients and to
compare among hypertension categories. We found
that severe hypertension is relatively common, with
almost one quarter of subjects having at least one
visit with severe hypertension. Further, in many
cases this represented more than a single isolated
spike, with over 40% having persistent or recurrent
severe elevations.
Factors associated with severe hypertension were
similar to those found in previous studies of poor BP
control. Subjects with severe hypertension were
older, more likely to be black, women, and had more
medical comorbidities than subjects with lower BPs.T
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Similarly, among those with severe hypertension,
those with recurrent or persistent elevations were
older and women. The recurrent group had more
medical comorbidities than those with persistent
elevations or the isolated severe group. Analyses of
National Health and Nutrition Examination Survey
data likewise found age and being black were
associated with poorer control.22,23 An analysis of
data from the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial, additionally
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found being woman, having diabetes and an
elevated creatinine were associated with lack of
control at follow-up.24 We found similar associa-
tions in our previous examination of factors asso-
ciated with poor BP control in this sample.15
We also found that patients with severe hyperten-
sion are often not treated aggressively enough. The
median follow-up time after a visit with severe
hypertension was 42 days, which is much longer
than the guideline-recommended interval. Although
medications were more likely to be increased as the
severity of BP category increased, this still occurred
at less than 50% of visits with severe hypertension
and many subjects with severe hypertension
remained uncontrolled at the end of the study.
Although mean number of medications increased by
BP category, within any category, including the
severe hypertension group, subjects with uncon-
trolled BP at study end tended to be on fewer
medications than controlled subjects. Further, a
significant percentage of the severe hypertension
group were not on adequate therapy at study end
and continued to have poorly controlled BP. Among
the severe hypertension subgroups, those on more
medications tended to be better controlled at study
end. Subjects with persistent severe hypertension
were more likely to have their medications
increased but were slightly less likely to be
controlled compared to the recurrent group.
Existing data specifically examining severe hyper-
tension epidemiology and management are very
limited, being based on small populations and select
samples. The largest observational study examined
outcomes in 142 emergency room (ER) patients
presenting with BPs X220mmHg systolic or
X120mmHg diastolic.12 Among those treated as
urgencies and discharged from the ER, the mean
time to a follow-up appointment was 21 days. Thirty
percent of subjects returned to the ER with uncon-
trolled hypertension, 14% with hypertensive com-
plications, within an average of 33 days. Drug
management was also only examined in the acute
ER setting. Longer-term use of drugs, BPs and
clinical outcomes were not tracked. A cross-sec-
tional Spanish study assessing cardiovascular risk
and comorbidities in hypertension patients attend-
ing primary care practices found the following
prevalences of BP categories among 1413 subjects:
controlled 3%, mild 50%, moderate 39%, severe
8%.13 The mean age of their sample was similar to
ours at 65.3 (11.4) years. Among high-risk patients
(based on comorbidities and absolute BP levels)
there was no medication change in 30%. No
information is given about the severe hypertension
subjects as a distinct group. Only one study
specifically examined subjects with severe hyper-
tension.12 Lalljie and Lalljie12 studied manage-
ment and BP outcomes in 48 subjects with severe
hypertension of 252 (19%) patients presenting
to a Jamaican hypertension specialty practice.
Follow-up data were only reported on 31 of these
subjects, of whom more than 50% achieved BP
control during up to 2 years of follow-up with
most requiring at least four drugs. Unlike our
study, subjects were younger (62% were o65 of
age), more likely to be women, with lower
baseline comorbidity rates (31% had diabetes, 21%
had heart failure and 15% had coronary artery
disease).
This study has a few caveats. It was performed in
a sample of predominantly male veterans with
relatively high disease burden and good access to
medical care and medications. Therefore, findings
may not be generalizable to other settings. Our data
predate VA quality performance data that show
improvement in control rates over time, such that
the current prevalence of severe hypertension is
likely lower.25 However, given the prevalence of
hypertension in the VA population has increased
from 37% in 1999 to 55–60% in 2006 (based on
ICD-9 codes), in absolute numbers this still likely
represents many patients with severe hyperten-
sion.26 We lack data on some management
aspects of severe hypertension subjects that may be
of interest such as referrals to hypertension
specialists (although we do know that less than
1.0% of these patients were seen in a hypertension
clinic) or investigations to exclude secondary hyper-
tension.
We have also demonstrated that the method used
to define the BP group, for example, highest average
BP at any visit vs the first visit of the 18-month
study period produces dramatically different values
with respect to severe hypertension prevalence.
Further deviation from the true prevalence may
result because BPs were obtained from the vitals file,
with only one BP available for almost 90% of visits;
we may be missing BPs present in provider notes.
In addition, we cannot exclude white coat hyper-
tension because we do not have access to home
BP measures or 24h ambulatory blood pressure
monitoring. However, in a previous study, we
found that provider notes contributed minimal
additional BP information beyond the vitals file,
including rare documentation of ambulatory or
home BPs.16
Our examination of hypertension management
was based on highest BP as opposed to the first
study BP because we wanted to determine provi-
ders’ responses to such high BPs. JNC 7, published
after our study, emphasizes that most patients will
require more than one antihypertensive drug to
achieve control.9 In our study using data through the
end of 2000, the majority of patients across all BP
groups were already on at least two medications,
with many also on a diuretic. Thus, we would not
expect substantially different findings with more
current data other than slightly lower rates of severe
hypertension as noted above. Our measure of
treatment adequacy does not account for medication
dosage and thus may be overestimating treatment
adequacy. It is possible that this may in part explain
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the lack of statistical difference between the propor-
tions controlled and uncontrolled in the severe
hypertension group at study end. However, this
still does not account for the fact that many subjects
in the severe hypertension group were not even
on adequate therapy based on number of
medications.
Although BP control, especially in severe hyper-
tension subjects, may be improved by treatment
intensification, specialist referral and investi-
gation for and management of secondary causes
of hypertension, we were unable to examine
reasons for lack of treatment intensification
and lacked data on referrals to hypertension
specialists (although we do know that less than
1.0% of these patients were seen in a hypertension
clinic) or on investigations to exclude secondary
hypertension. Other investigators have found clin-
ical uncertainty about true BP values to be a
prominent reason for lack of treatment intensifica-
tion.27 Whether this has a role in patients with such
high BPs is unclear.
In conclusion, among veterans with hyper-
tension, severe BP elevations are relatively
common with many patients having persistent or
recurrent elevations with inadequate follow-up
and intensification of therapy. This suggests that
clinical inertia is not just an issue among those with
mildly elevated BP. Given the increased cardio-
vascular risk associated with this degree of BP
elevation, there is a need for better understanding
of how these patients are being managed. In
addition, interventions are needed to overcome
clinical inertia and improve providers’ management
of hypertension, especially regarding severe hyper-
tension.
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